Emergent BioSolutions Inc. (EBS)

NYSE: EBS · Real-Time Price · USD
5.17
+0.43 (9.07%)
At close: Apr 2, 2025, 4:00 PM
5.00
-0.17 (-3.29%)
After-hours: Apr 2, 2025, 8:00 PM EDT
9.07%
Market Cap 280.92M
Revenue (ttm) 1.04B
Net Income (ttm) -190.60M
Shares Out 54.34M
EPS (ttm) -3.60
PE Ratio n/a
Forward PE 74.73
Dividend n/a
Ex-Dividend Date n/a
Volume 1,923,146
Open 4.62
Previous Close 4.74
Day's Range 4.75 - 5.35
52-Week Range 1.82 - 15.10
Beta 2.15
Analysts Strong Buy
Price Target 14.33 (+177.18%)
Earnings Date Apr 30, 2025

About EBS

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d... [Read more]

Sector Healthcare
IPO Date Nov 15, 2006
Employees 900
Stock Exchange NYSE
Ticker Symbol EBS
Full Company Profile

Financial Performance

In 2024, Emergent BioSolutions's revenue was $1.04 billion, a decrease of -0.54% compared to the previous year's $1.05 billion. Losses were -$190.60 million, -74.94% less than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EBS stock is "Strong Buy." The 12-month stock price forecast is $14.33, which is an increase of 177.18% from the latest price.

Price Target
$14.33
(177.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Emergent BioSolutions Announces Stock Repurchase Program

GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the compa...

2 days ago - GlobeNewsWire

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across th...

13 days ago - GlobeNewsWire

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada Emergent BioSolutions will lead commercial launch ef...

13 days ago - GlobeNewsWire

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facilit...

14 days ago - GlobeNewsWire

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for deli...

15 days ago - GlobeNewsWire

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring wides...

20 days ago - GlobeNewsWire

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions ...

21 days ago - GlobeNewsWire

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufactu...

23 days ago - GlobeNewsWire

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Offi...

4 weeks ago - Seeking Alpha

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2024.

4 weeks ago - GlobeNewsWire

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 Separately, Company leaders will attend and present at J.P. Morgan's 2025 Le...

6 weeks ago - GlobeNewsWire

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

GAITHERSBURG, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it is raising awareness of the Ready to Rescue initiative in New Orleans with pro footb...

7 weeks ago - GlobeNewsWire

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Africa CDC's support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo.

2 months ago - GlobeNewsWire

Emergent BioSolutions: Stock Is A Likely Winner In 2025

Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The ...

2 months ago - Seeking Alpha

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and ...

2 months ago - GlobeNewsWire

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Adminis...

2 months ago - GlobeNewsWire

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the wor...

3 months ago - GlobeNewsWire

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supp...

3 months ago - GlobeNewsWire

SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook

SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent B...

Other symbols: SIGA
4 months ago - Seeking Alpha

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence po...

5 months ago - Seeking Alpha

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.

5 months ago - Benzinga

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript

5 months ago - Seeking Alpha

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and ...

5 months ago - GlobeNewsWire

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial...

5 months ago - GlobeNewsWire

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasa...

6 months ago - GlobeNewsWire